New Drug Therapy for Kidney Stones: A Review of Cellulose Sodium Phosphate,Acetohydroxamic Acid,and Potassium Citrate

Abstract

Spanish

French

Kidney stones have an overall incidence of two to three percent in western countries. In many patients, the disease process is difficult to control and recurrence rates are high: 20 to 50 percent over the subsequent ten years. The pathogenesis and standard methods of treatment for the five major types of stones (i.e., calcium oxalate, struvite, calcium phosphate, uric acid, and cystine) are reviewed. Three new drugs are reviewed in the context of their roles in the selective treatment of kidney stones. Cellulose sodium phosphate (Calcibind) is a nonabsorbable ion-exchange resin with a limited indication for the treatment of calcium stones associated with absorptive hypercalciuria Type I. Acetohydroxamic acid (Lithostat) is an urease-inhibitor that is indicated as adjunctive therapy in patients with chronic urea-splitting urinary tract infections and struvite stones. Potassium citrate (Urocit) is an investigational agent that has clinical efficacy in patients with calcium oxalate and calcium phosphate stones who are hypocitraturic. In addition, potassium citrate is an alkalinizing agent that can be used in patients with uric acid stones.

Keywords

kidney stones cellulose sodium phosphate acetohydroxamic acid potassium citrate absorptive hypercalciuria Type I urease-inhibitors hypocitraturia

Get full access to this article

View all access options for this article.

References

Sierakowski

Finlayson

Landes

Finlayson

Sierakowski

. The frequency of urolithiasis in hospital discharge diagnoses in the United States. Invest Urol 1978; 15: 438–41.

Williams

. Long-term survey of 538 patients with upper urinary tract stones. Br J Urol 1963; 35: 416–37.

Blacklock

. The pattern of urolithiasis in the Royal Navy. In: Hodgkinson

Nordin

BEC

, eds. Proceedings of the Renal Stone Research Symposium. London: Churchill, 1969: 33.

Finlayson

. Physiochemical aspects of urolithiasis. Kidney Int 1978; 13: 344–60.

Fleisch

. Inhibitors and promoters of stone formation. Kidney Int 1978; 13: 361–71.

Broadus

Thier

. Metabolic basis of renal-stone disease. N Engl J Med 1979; 300: 839–45.

Stewart

Broadus

. The regulation of renal calcium excretion: An approach to hypercalciuria. Ann Rev Med 1981; 32: 457–73.

Coe

. Prevention of kidney stones. Am J Med 1981; 71: 514–6.

Pak

CYC

Britton

Peterson

. Ambulatory evaluation of nephrolithiasis. Am J Med 1980; 69: 19–30.

10.

Pak

CYC

Sakhaee

Crowther

Brinkley

. Evidence justifying a high fluid intake in treatment of nephrolithiasis. Ann Intern Med 1980; 93: 36–9.

11.

Smith

Van den Berg

Wilson

. Current concepts in nutrition: Nutrition and urolithiasis. N Engl J Med 1978; 298: 87–9.

12.

Maffly

. Nephrology. In: Rubenstein

Federman

, eds. Scientific American medicine. VIII. Nephrolithiasis. New York: Scientific American Incorporated, 1982; 10: VIII: 1–7.

13.

Griffith

. Infection-induced renal calculi. Kidney Int 1982; 21: 422–30.

14.

Griffith

. Struvite stones. Kidney Int 1978; 13: 372–82.

15.

Coe

. Clinical stone disease. In: Coe

Brenner

Stein

., eds. Contemporary issues in nephrology. 5. Nephrolithiasis. New York: Churchill Livingstone, 1980: 1–12.

16.

Smith

. Calcium-containing renal stones. Kidney Int 1978; 13: 383–9.

17.

Williams

. Oxalic acid and the hyperoxaluric syndromes. Kidney Int 1978; 13: 410–7.

18.

Coe

. Hyperuricosuric calcium oxalate nephrolithiasis. Kidney Int 1978; 13: 418–26.

19.

Parks

Coe

Favus

. Hyperparathyroidism in nephrolithiasis. Arch Intern Med 1980; 140: 1479–81.

20.

Coe

. Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria or no metabolic disorder. Ann Intern Med 1977; 87: 404–10.

21.

Brown

. Kidney stones. Postgrad Med 1982; 72: 124–38.

22.

Coe

Moran

Kavalich

. The contribution of dietary purine over-consumption to hyperuricosuria in calcium oxalate stone formers. J Chronic Dis 1976; 29: 793–800.

23.

Smith

. Enteric hyperoxaluria and other hyperoxaluric states. In: Coe

Brenner

Stein

., eds. Contemporary issues in nephrology. 5. Nephrolithiasis. New York: Churchill Livingstone, 1980: 136–64.

24.

Williams

Smith

. Primary hyperoxaluria. In: Stanbury

Wyngaarden

Frederickson

, eds. The metabolic basis of inherited disease. New York: McGraw-Hill, 1978: 182–204.

25.

Pak

CYC

Peters

Kadesky

. Is selective therapy of recurrent nephrolithiasis possible?Am J Med 1981; 71: 615–22.

26.

Yendt

Cohanim

. Prevention of calcium stones with thiazides. Kidney Int 1978; 13: 397–409.

27.

Maschio

Tessitore

D'angelo

. Prevention of calcium nephrolithiasis with low-dose thiazide, amiloride, and allopurinol. Am J Med 1981; 71: 623–6.

28.

Backman

Danielson

Johannson

Ljunghall

Wikstrom

. Effects of therapy of bendroflumethiazide in patients with recurrent renal calcium stones. Br J Urol 1979; 41: 175–7.

29.

Brocks

Dahl

Wolf

. Do thiazides prevent recurrent idiopathic renal calcium stones?Lancet 1981; 2: 124–5.

30.

Thomas

. Use of phosphates in patients with calcareous renal calculi. Kidney Int 1978; 13: 390–6.

31.

Ettinger

. Recurrent nephrolithiasis: Natural history and effect of phosphate therapy. Am J Med 1976; 61: 200–6.

32.

Lau

Wolf

Nussbaum

. Differing effects of acid versus neutral phosphate therapy of hypercalciuria. Kidney Int 1979; 16: 736–42.

33.

Griffith

Musher

. Pathogenesis of infection stones. In: Finlayson

Thomas

, eds. Proceedings of the International Colloquium on Urinary Stones. Gainesville: University of Florida, 1976: 54–65.

34.

Griffith

Bruce

Fishbein

. Infection (urease)-induced stones. In: Coe

Brenner

Stein

, eds. Contemporary issues in nephrology. 5. Nephrolithiasis. New York: Churchill Livingstone, 1980: 231–60.

35.

Griffith

Gibson

Clinton

Musher

. Acetohydroxamic acid: Clinical studies of a urease inhibitor in patients with staghorn renal calculi. J Urol 1978; 119: 9–15.

36.

Wojewski

Zajaczkowski

. The treatment of bilateral staghorn calculi of the kidneys. Int Urol Nephrol 1974; 5: 249–60.

37.

Singh

Chapman

Tresidder

Blandy

. The fate of unoperated staghorn calculous. Br J Urol 1973; 45: 581.

38.

Coe

. Uric acid and calcium oxalate nephrolithiasis. Kidney Int 1983; 24: 392–403.

39.

Thier

Segal

Fox

Blair

Rosenberg

. Cystinuria: Defective intestinal transport of dibasic amino acids and cystine. J Clin Invest 1965; 44: 442–8.

40.

Dent

Friedman

Green

Watson

LCA

. Treatment of cystinuria. Br Med J 1965; 1: 403–7.

41.

Pak

CYC

. Sodium cellulose phosphate: Mechanism of action and effect on mineral metabolism. J Clin Pharmacol 1973; 13: 15–27.

42.

Pak

CYC

Nicar

Northcutt

. The definition of the mechanism of hypercalciuria is necessary for the treatment of recurrent stone formers. Contrib Nephrol 1982; 33: 136–51.

43.

Pietrek

Kokot

. Treatment of patients with calcium-containing renal stones with cellulose phosphate. Br J Urol 1973; 45: 136–43.

44.

Hautmann

Hering

Lutzeyer

. Calcium oxalate stone disease: Effects and side effects of cellulose phosphate and succinate in long-term treatment of absorptive hypercalciuria or hyperoxaluria. J Urol 1978; 120: 712–5.

45.

Backman

Danielson

Johansson

Ljunghall

Wikstrom

. Treatment of recurrent calcium stone formation with cellulose phosphate. J Urol 1980; 123: 9–13.

46.

Pak

CYC

Delea

Bartter

. Successful treatment of recurrent nephrolithiasis (calcium stones) with cellulose phosphate. N Engl J Med 1974; 290: 175–80.

47.

Pak

CYC

. Clinical pharmacology of sodium cellulose phosphate. J Clin Pharmacol 1979; 19: 451–7.

48.

Pak

CYC

. A cautious use of sodium cellulose phosphate in the management of calcium nephrolithiasis. Invest Urol 1981; 19: 187–90.

49.

Package insert. Calcibind. Mission Pharmacal Company, San Antonio, Texas, December 1982.

50.

Hayashi

Kaplan

Pak

CYC

. Effect of sodium cellulose phosphate therapy in crystallization of calcium oxalate in urine. Metabolism 1975; 24: 1273–8.

51.

Robertson

Peacock

Nordin

BEC

. Calcium oxalate crystalluria and urine saturation in recurrent renal stone-formers. Clin Sci 1971; 40: 365–74.

52.

Robertson

Peacock

Nordin

BEC

. Measurement of activity products in urine from stone-formers and normal subjects. In: Finlayson

Hench

Smith

, eds. Urolithiasis: Physical aspects. Washington, DC: National Academy of Sciences, 1972: 79–95.

53.

Johansson

Backman

Danielson

Fellstrom

Ljunghall

Wikstrom

. Biochemical and clinical effects of the prophylactic treatment of renal calcium stones with magnesium hydroxide. J Urol 1980; 124: 770–4.

54.

Griffith

Musher

Itin

. Urease: The primary cause of infection-induced urinary stones. Invest Urol 1976; 13: 346–50.

55.

Musher

Saenz

Griffith

. Interaction between acetohydroxamic acid and twelve antibiotics against fourteen gram-negative pathogens. Antimicrob Agents Chemother 1974; 5: 106–10.

56.

Musher

Griffith

Yawn

Rossen

. Role of urease in pyelonephritis resulting from urinary tract infection with Proteus. J Infect Dis 1975; 131: 177–81.

57.

Griffith

Musher

. Prevention of infected urinary stones by urease inhibition. Invest Urol 1973; 11: 228–33.

58.

Feldman

Putcha

Griffith

. Pharmacokinetics of acetohydroxamic acid. Invest Urol 1978; 15: 498–501.

59.

Wolpert

Hofmann

Summerskill

WHJ

. Synthesis and metabolism of labeled acetohydroxamic acid, a urease inhibitor. Proc Soc Exp Biol Med 1971; 136: 592–6.

60.

MaclAren

. The influence of acetohydroxamic acid on experimental Proteus pyelonephritis. Invest Urol 1974; 12: 146–9.

61.

Griffith

Moskowitz

Carlton

. Adjunctive chemotherapy of infection-induced staghorn calculi. J Urol 1979; 121: 711–5.

62.

Martelli

Buli

Cortecchia

. Acetohydroxamic acid therapy in infected renal stones. Urology 1981; 17: 320–2.

63.

Burr

Nuseibeh

. The effect of oral acetohydroxamic acid on urinary saturation in stone-forming spinal cord patients. Br J Urol 1983; 55: 162–5.

64.

Rodman

Williams

Peterson

. Partial dissolution of struvite calculus with oral acetohydroxamic acid. Urology 1983; 22: 410–2.

65.

Package insert. Lithostat. Mission Pharmacal Company. San Antonio, Texas, June 1983.

66.

Philips

Sternberg

Schwartz

Cronin

Sodergren

Vidal

. Hydroxyurea. I. Acute cell death in proliferating tissues in rats. Cancer Res 1967; 27: 61–75.

67.

Meyer

Smith

. Growth of calcium oxalate crystals. II. Inhibition by natural urinary crystal growth inhibitors. Invest Urol 1975; 13: 36–9.

68.

Meyer

Thomas

. Trace metal-citric acid complexes as inhibitors of calcification and crystal growth. II. Effects of Fe(III), Cr(III), and Al(III) complexes on calcium oxalate crystal growth. J Urol 1982; 128: 1376–8.

69.

Meyer

Thomas

Jr . Trace metal-citric acid complexes as inhibitors of calcification and crystal growth. I. Effects of Fe (III), Cr (III), and Al (III) complexes on calcium phosphate crystal growth. J Urol 1982; 128: 1372–5.

70.

Bisaz

Felix

Neuman

Fleisch

. Quantitative determination of inhibitors of calcium phosphate precipitation in whole urine. Mines Electrolyte Metab 1978; 1: 74–83.

71.

Uhlir

. The peroral dissolution of renal calculi. J Urol 1970; 104: 239–47.

72.

Sakhaee

Nicar

Hill

Pak

CYC

. Contrasting effects of potassium citrate and sodium citrate therapies on urinary chemistries and crystallization of stone-forming salts. Kidney Int 1983; 24: 348–52.

73.

Sakhaee

Nicar

Jacobsen

Pak

CYC

. Potassium alkali therapy of uric acid lithiasis may prevent complication of calcium stones (abstract). Clin Res 1982; 30: 403A.

74.

Pak

CYC

Skurla

Brinkley

Sakhaee

. Augmentation of renal citrate excretion by oral potassium citrate administration: Time-course, dose frequency schedule, and dose response relationship. J Clin Pharmacol 1984; 24: 19–26.

75.

Nicar

Peterson

Pak

CYC

. Utility of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. J Urol 1984; 131: 430–3.

76.

Pak

CYC

Sakhaee

Fuller

. Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy. Trans Assoc Am Physicians 1983; 96: 294–305.

77.

Nicar

Skurla

Sakhaee

Pak

CYC

. Low urinary citrate excretion in nephrolithiasis. Urology 1983; 21: 8–14.